Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on November 6, 2017, covering events occurring on November 1 and November 2, 2017. The report details the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics
- Shares Issued: 2,210,000 shares of common stock in the primary offering.
- Option Exercise: Underwriters exercised a 30-day option to purchase an additional 331,500 shares.
- Offering Price: $27.25 per share.
- Net Proceeds: Approximately $64.8 million received after deducting underwriting discounts, commissions, and estimated offering expenses.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels as this is a transaction report rather than a periodic financial statement.
Material Changes
The primary material change is the increase in the company's capital base through the issuance of 2,541,500 total shares (primary offering plus option exercise). This transaction significantly alters the company's liquidity position by injecting approximately $64.8 million in net cash proceeds.
Guidance, Outlook, and Risks
Management Commentary: The company utilized the proceeds to fund its operations and growth, though specific allocation details are not provided in this summary text. The offering was conducted pursuant to an effective Registration Statement on Form S-3.
Risks and Contingencies: The Underwriting Agreement includes customary representations, warranties, and covenants. The Company agreed to indemnify the underwriters (Jefferies LLC and William Blair & Company, L.L.C.) against certain liabilities incurred in connection with the Offering.
Investor Verification Checklist
- Verify the final closing date of November 6, 2017, and confirm the actual cash received matches the reported $64.8 million net proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification clauses.
- Confirm the dilution impact of the 2,541,500 new shares on existing shareholders.
- Check subsequent filings for the specific use of proceeds as outlined in the prospectus supplement.